MEIS1的下调会损害CD34+ NPM1突变的急性髓系白血病细胞的长期扩增。 - Suppr

Suppr

超能文献

Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells.

作者信息

Woolthuis C M, Han L, Verkaik-Schakel R N, van Gosliga D, Kluin P M, Vellenga E, Schuringa J J, Huls G

出版信息

Leukemia. 2012 Apr;26(4):848-53. doi: 10.1038/leu.2011.277. Epub 2011 Oct 11.

DOI:10.1038/leu.2011.277

PMID:21986840

Abstract

摘要

相似文献

Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells.MEIS1的下调会损害CD34+ NPM1突变的急性髓系白血病细胞的长期扩增。

Leukemia. 2012 Apr;26(4):848-53. doi: 10.1038/leu.2011.277. Epub 2011 Oct 11.

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.采用频繁和罕见的患者特异性 NPM1 突变对急性髓系白血病进行微小残留病监测。

Am J Hematol. 2010 Dec;85(12):926-9. doi: 10.1002/ajh.21879.

Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.伴有FLT3串联重复和核磷蛋白突变的急性髓系白血病中髓单核细胞标志物的独特表达及CD34的下调

Eur J Haematol. 2007 Jul;79(1):17-24. doi: 10.1111/j.1600-0609.2007.00866.x.

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.NPM1 突变型急性髓系白血病微小残留病监测：德国-奥地利急性髓系白血病研究组的一项研究。

J Clin Oncol. 2011 Jul 1;29(19):2709-16. doi: 10.1200/JCO.2011.35.0371. Epub 2011 May 9.

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.Flt3和STAT5A的组成性激活增强了造血干细胞的自我更新能力并改变了其分化。

Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16. doi: 10.1016/j.exphem.2007.01.018.

The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.HOXA4和MEIS1的联合表达是急性髓系白血病患者的一个独立预后因素。

Eur J Haematol. 2009 Nov;83(5):439-48. doi: 10.1111/j.1600-0609.2009.01309.x. Epub 2009 Jun 25.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.伴有核磷蛋白（NPM1）突变的急性髓系白血病：分子、病理及临床特征

Cancer Treat Res. 2010;145:149-68. doi: 10.1007/978-0-387-69259-3_9.

Role of nucleophosmin in acute myeloid leukemia.核磷蛋白在急性髓系白血病中的作用。

Expert Rev Anticancer Ther. 2009 Sep;9(9):1283-94. doi: 10.1586/era.09.84.

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.细胞质突变型核仁磷酸蛋白在原发性白血病细胞以及重症联合免疫缺陷（SCID）小鼠的NPMc+急性髓系白血病异种移植模型中是稳定的。

Haematologica. 2008 May;93(5):775-9. doi: 10.3324/haematol.12225. Epub 2008 Mar 26.

Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.急性早幼粒细胞白血病与伴有核仁磷酸蛋白基因突变的 CD15-CD34-HLA-DR- 急性髓系白血病的免疫表型鉴别。

Hematol Oncol. 2012 Sep;30(3):109-14. doi: 10.1002/hon.1011. Epub 2011 Aug 3.

引用本文的文献

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia.新型Menin-KMT2A抑制剂JNJ-75276617（即Bleximenib）可损害急性髓系白血病的长期增殖和免疫逃逸能力。

Haematologica. 2025 Jun 1;110(6):1278-1291. doi: 10.3324/haematol.2024.285616. Epub 2024 Dec 19.

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.强效、选择性的 menin-KMT2A 抑制剂 JNJ-75276617（bleximenib）在 KMT2A 和 NPM1 改变的白血病中的临床前疗效。

Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480.

Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.组合遗传学揭示了 Dock1-Rac2 轴作为治疗 NPM1;Cohesin 突变 AML 的潜在靶点。

Leukemia. 2022 Aug;36(8):2032-2041. doi: 10.1038/s41375-022-01632-y. Epub 2022 Jul 1.

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice.Npm1 杂合不足与 MEIS1 协同作用足以在小鼠中诱导 AML。

Blood Adv. 2023 Feb 14;7(3):351-364. doi: 10.1182/bloodadvances.2022007015.

A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML.整体观白血病发生：黏合蛋白复合体和 AML 中的其他驱动突变。

Neoplasia. 2021 Mar;23(3):337-347. doi: 10.1016/j.neo.2021.01.003. Epub 2021 Feb 20.

Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.Menin 抑制剂 MI-3454 诱导 MLL1 重排和 NPM1 突变的白血病模型缓解。

J Clin Invest. 2020 Feb 3;130(2):981-997. doi: 10.1172/JCI129126.

Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation.BCR-ABL诱导的缺氧样特征可能改变谷氨酰胺摄取以维持氧化磷酸化。

PLoS One. 2016 Apr 7;11(4):e0153226. doi: 10.1371/journal.pone.0153226. eCollection 2016.

Analyse multiple disease subtypes and build associated gene networks using genome-wide expression profiles.利用全基因组表达谱分析多种疾病亚型并构建相关基因网络。

BMC Genomics. 2015;16 Suppl 5(Suppl 5):S3. doi: 10.1186/1471-2164-16-S5-S3. Epub 2015 May 26.

Regulation of MEIS1 by distal enhancer elements in acute leukemia.急性白血病中远端增强子元件对 MEIS1 的调控。

Leukemia. 2014 Jan;28(1):138-46. doi: 10.1038/leu.2013.260. Epub 2013 Sep 11.

A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis.单个中心分析核仁磷酸蛋白在急性髓细胞白血病中的作用：联合免疫组织化学与分子突变分析的价值。

Haematologica. 2013 Oct;98(10):1532-8. doi: 10.3324/haematol.2012.079806. Epub 2013 May 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验